Foundayo is Eli Lilly's brand name for orforglipron, a small-molecule GLP-1 receptor agonist. FDA-approved April 2026 for chronic weight management, it became the first oral GLP-1 agonist approved for obesity (semaglutide's oral version, Rybelsus, is approved for Type 2 diabetes only). Foundayo's approval was unusually fast — about three years from first registrational data readout, the fastest weight-loss approval in two decades.
What makes Foundayo different
Foundayo is not a peptide. Semaglutide, tirzepatide, and liraglutide are all peptides — chains of amino acids that must be either injected or formulated with elaborate absorption enhancers (the way Rybelsus is) to survive the gut. Orforglipron is a small molecule, taken as a daily tablet. There is no fasting window required (unlike Rybelsus, which requires a 30-minute fast after dosing).
ATTAIN trial readouts
The ATTAIN-1 and ATTAIN-2 trials showed mean weight loss of approximately 13–14% at 72 weeks at the highest dose, with a side-effect profile similar to other GLP-1 agonists (GI symptoms leading). This is meaningful but less than tirzepatide's SURMOUNT trials at 21–22%. Foundayo's positioning is convenience over peak efficacy.
Dosing
Foundayo titrates from a 3 mg starter dose to a 36 mg maximum dose over a 16-week period. Patients take one tablet daily. There is no refrigeration requirement.
Pricing in 2026
LillyDirect lists Foundayo at $199/month cash-pay through April 2027, with commercial insurance coverage rolling out gradually through 2026. Compounded versions are not yet available because orforglipron is not currently on the FDA drug shortage list.
Who should consider Foundayo
- Patients with injection aversion that would otherwise be a barrier to GLP-1 therapy
- Patients who travel frequently and find refrigerated injectables logistically difficult
- Patients who want a starting GLP-1 with a lower entry to titration
- Patients whose insurance covers Foundayo but not injectable Wegovy
Who should stick with injectable
- Patients targeting maximum weight loss — tirzepatide injectable still leads on efficacy
- Patients on compounded therapy with established titration — there's no compelling reason to switch
- Patients with adherence challenges around daily medication (weekly injection is often easier)
NexLife scored highest on our rubric (94/100) for comprehensive GLP-1 care. Flat-rate pricing across full titration, labs included, MD/DO oversight, both 503A and 503B pharmacy partners.
This article was authored by Eduard Cristea and clinically reviewed by Dr. A. Goher, MD. Health Technology Researcher & Publisher. See our methodology and affiliate disclosure.